Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;10(1):2428129.
doi: 10.1080/20565623.2024.2428129. Epub 2024 Nov 19.

Panduratin A mitigates inflammation and oxidative stress in DSS-induced colitis mice model

Abdelrahim Alqudah  1 , Esam Qnais  2 , Omar Gammoh  3 , Yousra Bseiso  2 , Mohammed Wedyan  2 , Muna Oqal  4
Affiliations

Panduratin A mitigates inflammation and oxidative stress in DSS-induced colitis mice model

Abdelrahim Alqudah et al. Future Sci OA. 2024 Dec.

Abstract

Aim: This study explored Panduratin A's protective effects against DSS-induced colitis in mice, focusing on reducing inflammation and oxidative stress in the colon.

Methods: Mice were treated with dextran sodium sulfate (DSS) and Panduratin A (3, 6, 18 mg/kg), and changes in body weight, colon length, Disease Activity Index (DAI), histopathology, inflammation markers including tumor necrosis factor- α (TNF-α), Interleukin-1 β (IL-1β), Myeloperoxidase (MPO), and oxidative stress, Malondialdehyde (MDA) were evaluated.

Results: Panduratin A significantly reversed DSS-induced symptoms, including body weight loss, colonic length shortening, and DAI increase, while reducing histopathological damage. It lowered inflammatory markers and oxidative stress, suppressed NF-κB activation, and enhanced Nrf2 and HO-1 expression.

Conclusion: Panduratin A shows promise as a colitis treatment, warranting further research for broader clinical application.

Keywords: DSS-induced colitis; Panduratin A; anti-inflammatory; oxidative stress; ulcerative colitis.

Plain language summary

In this study, we looked at how a natural compound called Panduratin A might help fight a common type of bowel inflammation called colitis in mice. This inflammation can cause pain and other health problems. We treated mice with a substance that causes colitis, then gave some of them Panduratin A to see if it would help. We watched how their weight changed, how long their colons were, and how much inflammation they had. Our results were promising: the mice treated with Panduratin A were healthier than those that weren’t. They lost less weight, had longer colons, and showed fewer signs of inflammation. This suggests that Panduratin A could be a new way to protect against bowel inflammation. More studies are needed to see if this treatment could work in people too.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
The impact of Panduratin A on histological changes in colonic tissues during DSS-induced colitis. Representative images depict colonic tissue samples from various groups of mice: (A) Control group, (B) DSS group, (C) DSS + Panduratin A (3 mg/kg) group, (D) DSS + Panduratin A (6 mg/kg) group, (E) DSS + Panduratin A (18 mg/kg) group, (F) DSS + SUL. The images were stained with hematoxylin and eosin and magnified at 200×. The colonic tissues in the DSS group display extensive epithelial damage, crypt abscesses, and a loss of goblet cells. n = 10, DSS, dextran sodium sulfate; SUL, sulfasalazine.
Figure 2.
Figure 2.
The impact of Panduratin A on DSS-induced colitis through various parameters. (A) Body weight change is depicted for each group. (B) The disease activity index is shown. (C) The lengths of colons for each group are measured and presented. The values presented in the figure represent the mean ± SEM (standard error of the mean) of three parallel measurements. Statistical significance is denoted as #p < 0.01 vs. control group, *p < 0.05, **p < 0.01 vs. DSS group. n = 10, DSS, dextran sodium sulfate; SUL, sulfasalazine.
Figure 3.
Figure 3.
The influence of Panduratin A on DSS-induced (A) MPO (myeloperoxidase) activity, (B) MDA (malondialdehyde), (C) TNF-α (tumor necrosis factor-alpha) and (D) IL-1β (interleukin-1 beta) content. The values presented in the figure represent the mean ± SEM of three parallel measurements. Statistical significance is denoted as #p < 0.01 vs. control group, *p < 0.05, **p < 0.01 vs. DSS group. n = 10, DSS, dextran sodium sulfate; SUL, sulfasalazine.
Figure 4.
Figure 4.
The impact of Panduratin A on DSS-induced NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation. The values depicted in the figure represent the mean ± SEM of three parallel measurements. Significance levels are indicated as #p < 0.01 vs. control group, *p < 0.05, **p < 0.01 vs. DSS group. n = 10, DSS, dextran sodium sulfate; SUL, sulfasalazine.
Figure 5.
Figure 5.
The effects of Panduratin A on the expression of (A) Nrf2 (nuclear factor erythroid 2-related factor 2) and (B) HO-1 (heme oxygenase-1). The values displayed in the figure represent the mean ± SEM of three parallel measurements. Significance levels are indicated as #p < 0.01 vs. control group, *p < 0.05, **p < 0.01 vs. DSS group. n = 10, DSS, dextran sodium sulfate; SUL, sulfasalazine.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Schultsz C, Van den Berg FM, Kate FWT, et al. . The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology. 1999;117(5):1089–1097. doi: 10.1016/s0016-5085(99)70393-8 - DOI - PubMed
    1. Wong VKC, Yu L, Cho CH.. Protective effect of polysaccharides from Angelica sinensis on ulcerative colitis in rats. Inflammopharmacology. 2008;16(4):162–167. doi: 10.1007/s10787-007-0026-5 - DOI - PubMed
    1. Loddo I, Romano C.. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Front Immunol. 2015;6(NOV):159896. doi: 10.3389/fimmu.2015.00551 - DOI - PMC - PubMed
    1. Kulaylat MN, Dayton MT.. Ulcerative colitis and cancer. J Surg Oncol. 2010;101(8):706–712. doi: 10.1002/jso.21505 - DOI - PubMed
    1. Gopal E, Miyauchi S, Martin PM, et al. . Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract. Pharm Res. 2007;24(3):575–584. doi: 10.1007/s11095-006-9176-1 - DOI - PubMed

LinkOut - more resources